Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1
ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress
Read more -
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress
Data presented will reinforce the potential to shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV
Read more -
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices
ViiV Healthcare work with clinical staff at 18 diverse practice sites across different healthcare systems in France, Spain, Belgium, Germany
Read more -
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases
Read more -
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant.
Read more -
GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer
This opinion follows the expansion of Zejula’s indication in the US with approval by the US Food and Drug Administration earlier this year.
Read more -
Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
This confirmation follows the announcement on 31 July of advanced discussions between the companies and the EC.
Read more -
GSK highlights scientific advances across its growing oncology portfolio at ESMO Virtual Congress 2020
New data from the GARNET study to be presented as a late-breaking abstract
Read more -
FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm
Read more -
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Over 400 participants being enrolled in Phase 1/2 study.
Read more -
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
Phase 2/3 study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19.
Read more -
GSK presents promising phase 2a data for chronic hepatitis B treatment
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
Read more -
European Commission approves BLENREP (belantamab mafodotin) for the treatment of patients with relapsed and refractory multiple myeloma
BLENREP is a first-in-class humanised anti-BCMA treatment for patients whose disease has progressed despite the current standard of care.
Read more -
GSK announces first participant vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate
The trial will evaluate safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo.
Read more -
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
BLENREP is the fifth major medicine approval for GSK in 2020
Read more -
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system
Read more -
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
Read more -
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
Read more -
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
Read more -
GSK receives positive CHMP opinion recommending approval of belantamab mafodotin for the treatment of relapsed and refractory multiple myeloma
If approved, it will be the second major regulatory milestone for GSK’s oncology portfolio this year.
Read more
Find out more about us
-
About us
Uniting science, technology and talent to get ahead of disease together
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself